Research output per year
Research output per year
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial
TREATT Trial Investigators, Hughes, T. & Yeung, D., Jan 2025, In: The Lancet Haematology. 12, 1, p. e14-e22Research output: Contribution to journal › Article › peer-review
2 Citations (Scopus) -
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
Eadie, L. N., Lagonik, E., Page, E. C., Schutz, C. E., Heatley, S. L., McClure, B. J., Forgione, M. O., Yeung, D. T., Hughes, T. P. & White, D. L., 2024, (Accepted/In press) In: Blood.Research output: Contribution to journal › Article › peer-review
-
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia
Chee, L., Lee, N., Grigg, A., Chen, M., Schwarer, A., Szer, J., Ratnasingam, S., Raj, S., Lukito, P., Yeung, D., Hughes, T. & Shanmuganathan, N., 2024, (Accepted/In press) In: Internal Medicine Journal.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus)
Prizes
Activities
-
SAHMRI Precision Cancer Medicine Theme Seminar Series
Eadie, L. (Participant)
10 Apr 2024Activity: Other
-
Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting
Eadie, L. (Participant)
1 Aug 2024 → 3 Aug 2024Activity: Other
-
New Directions in Leukaemia Research (NDLR)
Eadie, L. (Participant)
4 Mar 2024 → 6 Mar 2024Activity: Other